PCN11 The potential long-term comparative effectiveness of larotrectinib vs. lenvatinib or sorafenib for treatment of NTRK fusion-positive metastatic thyroid cancer
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.103
https://www.valueinhealthjournal.com/article/S1098-3015(21)00320-X/fulltext
Title :
PCN11 The potential long-term comparative effectiveness of larotrectinib vs. lenvatinib or sorafenib for treatment of NTRK fusion-positive metastatic thyroid cancer
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00320-X&doi=10.1016/j.jval.2021.04.103
First page :
Section Title :
Open access? :
No
Section Order :
10497